Ryan Wilcox
University of Michigan Rogel Cancer Center · University of Michigal Rogel Cancer Center · Int Med-Hematology/Oncology - Faculty and Staff
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
9
all conditions, ClinicalTrials.gov
NIH grants tied to them
8
NIH RePORTER
Trial papers
96
PubMed author-name match
Trials
Studies that name Ryan Wilcox as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 03:43 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05956041 · Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell LymphomasUniversity of Michigan Rogel Cancer Center · recruiting · Cutaneous T Cell Lymphoma, Fungoides Mycosis Sezary Syndrome · principal investigator
- Ph2NCT04858256 · Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative NeoplasmsUniversity of Michigan Rogel Cancer Center · recruiting · T-Cell Neoplasm, Lymphoproliferative Disorders · principal investigator
- Ph2NCT03927105 · Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell LymphomaUniversity of Michigan Rogel Cancer Center · completed · Peripheral T Cell Lymphoma · principal investigator
- Ph1NCT03601819 · Pacritinib in Relapsed/Refractory Lymphoproliferative DisordersUniversity of Michigan Rogel Cancer Center · terminated · Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Chronic Lymphocytic Leukemia · principal investigator
- Ph1/Ph2NCT03547700 · Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)University of Michigan Rogel Cancer Center · terminated · Lymphoma, T-Cell, Peripheral · principal investigator
- Early Ph1NCT03235869 · Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell LymphomaUniversity of Michigan Rogel Cancer Center · withdrawn · Cutaneous T Cell Lymphoma · principal investigator
- Ph1/Ph2NCT02677948 · Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)University of Michigan Rogel Cancer Center · withdrawn · Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic · principal investigator
- Ph2NCT02400463 · A Pilot Study of Ruxolitinib in Secondary Hemophagocytic SyndromeUniversity of Michigan Rogel Cancer Center · completed · Hemophagocytic Syndrome (HPS) · principal investigator
- Ph2NCT02158975 · Open-label, Phase II Study of MLN9708 in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell LymphomasUniversity of Michigan Rogel Cancer Center · completed · Lymphoma, T-Cell · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 03:43 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Cancer Hematopoiesis and Immunology (CHI)P30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · fiscal years 2025 to 2026 · $78,773 awarded in 2026Same name and institution; not confirmed by an ID
- Notch ligands as oncogenic drivers and therapeutic targets in T-cell lymphomasR01CA278976 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · fiscal years 2024 to 2026 · $602,869 awarded in 2026Same name and institution; not confirmed by an ID
- Novel Multi-targeted Strategies Targeting T-cell Lymphomas and their MicroenvironmentR01CA306891 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · fiscal years 2026 · $646,920 awarded in 2026Same name and institution; not confirmed by an ID
- Novel therapeutic strategies targeting the enhancer landscape in high-risk T-cell lymphomas.R21CA316106 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · fiscal years 2026 · $401,115 awarded in 2026Same name and institution; not confirmed by an ID
- Pacritinib in rel/refr T-cell lymphomasR01CA265929 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · fiscal years 2021 to 2025 · $1,084,365 awarded in 2025Grant number is on one of their registry trials
- THE T-CELL RECEPTOR'S ROLE IN T-CELL LYMPHOMA PATHOGENESISR37CA233476 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · fiscal years 2019 to 2025 · $320,391 awarded in 2025Same name and institution; not confirmed by an ID
- Notch and GATA-3 as novel therapeutic targets in T-cell lymphomasR01CA236722 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · fiscal years 2020 to 2024 · $339,008 awarded in 2024Same name and institution; not confirmed by an ID
- The role of GATA-3 in T-cell lymphomasK08CA172215 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · fiscal years 2013 to 2017 · $178,618 awarded in 2017Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 03:43 UTC. The ranking covers the 200 most relevant of 96 PubMed records, and a shared surname and initials can bring in a namesake. All 96 on PubMed
- 3,147 citationsRCR 75.1
- 979 citationsRCR 38.2
- 963 citationsRCR 22.3
- 728 citationsRCR 17.5
- Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.N Engl J Med · 2013541 citationsRCR 16.4
- Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.J Am Coll Cardiol · 2007401 citationsRCR 9.7
- 358 citationsRCR 8.6
- 329 citationsRCR 7.5
- 327 citationsRCR 8.0
- Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial.Lancet · 2003298 citationsRCR 6.3